A Clinical Study of 9MW2821 Monotherapy or Combined With Other Anticancer Therapy in Advanced Solid Tumors

Inclusion criteria

• Competent to comprehend, sign, and date an independent ethics committee/institutional review board/research ethics board (IEC/IRB/REB) approved informed consent form.
• Male or female subjects aged 18 to 75 years (including 18 and 75 years).
• Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1.
• Histopathological diagnosed of recurrent or locally advanced or metastatic solid tumors.
• Adequate tumor tissues submitted for test.
• Life expectancy of ≥ 12 weeks.
• Subjects must have measurable disease according to RECIST (version 1.1).
• Adequate organ functions.
• Sexually active fertile subjects, and their partners, must agree to use contraception during the study and at least 6 months after termination of study therapy.
• Subjects are willing to follow study procedures.

Exclusion criteria

• History of another malignancy within 3 years before the first dose of study drug.
• Ongoing clinically significant toxicities related to prior treatment.
• Grade ≥ 2 peripheral neuropathy.
• Severe or uncontrolled gastrointestinal diseases.
• Other severe or uncontrolled diseases, including severe respiratory diseases, cardiovascular and cerebrovascular diseases of clinical significance.
• Experienced clinically significant bleeding or had a clear bleeding tendency.
• Central nervous system (CNS) metastasis and/or malignant meningitis.
• Clinically significant pleural, abdominal, or pericardial effusion.
• Chemotherapy or radiotherapy within 21 days prior to the first dose of study drug;
• Known sensitivity to any of the ingredients of the investigational product; History of drug abuse or mental illness.
• Pregnant and lactating women.
• Other conditions that, in the Investigator's opinion, may not be suitable for the subject to be enrolled.